Uveitis

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:98715
Who is this for?
Show terms as
1FDA treatments18Active trials72Specialists8Treatment centers1Financial resources

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Orphanet ↗NORD ↗

FDA & Trial Timeline

10 events
Jun 2025Metagenomics for Ocular Inflammation

Moorfields Eye Hospital NHS Foundation Trust

TrialRECRUITING
Jun 2025Therapeutic Drug Monitoring-baSed adalimuMab De-escalatiOn in nOn-infecTious cHronic Uveitis

Centre Hospitalier Universitaire de Saint Etienne — PHASE4

TrialNOT YET RECRUITING
Apr 2025Demographic Data and Clinical Presentation of Pediatric Uveitis

Assiut University

TrialNOT YET RECRUITING
Jan 2025Study of Risk Factors for Therapeutic Failure in Chronic Non-Infectious Uveitis After First-Line Immunosuppressive Therapy

Centre Hospitalier Universitaire, Amiens

TrialACTIVE NOT RECRUITING
Sep 2024Suprachoroidal Triamcinolone in Macular Edema for Patients With Non-Infectious Uveitis Resistant to Subtenon Triamcinolon

University of Baghdad — EARLY_PHASE1

TrialRECRUITING
Aug 2024Mindfulness Approach for Reducing Anxiety and Gloom in Ocular Inflammatory Diseases

University of California, San Francisco — NA

TrialACTIVE NOT RECRUITING
May 2024Safety, Tolerability, and Distribution of Laquinimod Eye Drops : The LION Study

Quan Dong Nguyen — PHASE1

TrialRECRUITING
May 2024Incidence of Macular Edema in a Uveitis Population

Aalborg University Hospital

TrialACTIVE NOT RECRUITING
Mar 2024Effect of Immunosuppressants With Adalimumab Biosimilars vs Corticosteroids on Noninfectious Uveitis

Zhongshan Ophthalmic Center, Sun Yat-sen University — NA

TrialACTIVE NOT RECRUITING
Mar 2024Treatment FOr Corticosteroid Dependent UveitiS

Assistance Publique - Hôpitaux de Paris — PHASE3

TrialNOT YET RECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

1 available

Vitrasert Implant

Ganciclovir intravitreal implant· Bausch & Lomb Surgical, Chiron Vision Products

Treatment of CMV retinitis in patients with acquired immunodeficiency syndrome

Clinical Trials

18 recruitingView all trials with filters →
Phase 41 trial
Assessment of Safety , Clinical Efficacy with QLETLI in Non-infectious Uveitis (UV)
Phase 4
Active
PI: Peizeng Yang, M.D (1 Youyi Road, Yuzhong District, Chongqing, China) · Sites: Beijing; Changsha +5 more · Age: 1870 yrs
Phase 21 trial
Intravitreal Adalimumab Versus Subcutaneous Adalimumab in Non-infectious Uveitis
Phase 2
Actively Recruiting
PI: Rola N Hamam, MD (American University of Beirut Medical Center) · Sites: Beirut · Age: 1899 yrs
Phase 11 trial
Safety, Tolerability, and Distribution of Laquinimod Eye Drops : The LION Study
Phase 1
Actively Recruiting
· Sites: Palo Alto, California · Age: 1899 yrs
N/A3 trials
Effect of Immunosuppressants With Adalimumab Biosimilars vs Corticosteroids on Noninfectious Uveitis
N/A
Active
PI: Wei Chi (Shenzhen Eye Hospital) · Sites: Shenzhen, Guangdong · Age: 1870 yrs
Screening for Oculocerebral Lymphoma with the Phenotype of NK Cells in Patients with Uveitis
N/A
Actively Recruiting
· Sites: Lyon; Lyon · Age: 1899 yrs
Mindfulness Approach for Reducing Anxiety and Gloom in Ocular Inflammatory Diseases
N/A
Active
PI: Nisha Acharya, MD, MS (UCSF, Proctor Foundation) · Sites: San Francisco, California · Age: 1899 yrs
Other10 trials
Study of Risk Factors for Therapeutic Failure in Chronic Non-Infectious Uveitis After First-Line Immunosuppressive Therapy
Active
· Sites: Salouël · Age: 1899 yrs
Incidence of Macular Edema in a Uveitis Population
Active
PI: Lasse J Cehofski, MD, P.h.d (Aalborg University Hospital) · Sites: Aalborg, North Denmark
UNICORNS: Uveitis in Childhood Prospective National Cohort Study
Active
PI: Ameenat L Solebo (University College London (UCL) Great Ormond Stree) · Sites: Belfast; Birmingham +29 more · Age: 018 yrs
Lyon Uveitis Study
Actively Recruiting
· Sites: Lyon · Age: 1899 yrs
Imaging Quantification of Inflammation (IQI)
Active
PI: Sunil K Srivastava, MD (The Cleveland Clinic) · Sites: Cleveland, Ohio · Age: 1880 yrs
Genetics of Uveitis
Actively Recruiting
PI: Sunil K. Srivastava, M.D. (The Cleveland Clinic) · Sites: Cleveland, Ohio · Age: 699 yrs
Metagenomics for Ocular Inflammation
Actively Recruiting
· Sites: London
A Study of YUTIQ® 0.18 mg Intravitreal Implant for the Management of Chronic Non-infectious Uveitis
Actively Recruiting
· Sites: Tianjin, Tianjin Municipality · Age: 1870 yrs
RChildUV:Study on Non-infectious Chronic Uveitis in Pediatric Age
Actively Recruiting
· Sites: Kansas City, Kansas; Boston, Massachusetts +17 more · Age: 116 yrs
The Cohort Study of Uveitis Patients
Actively Recruiting
· Sites: Guangzhou, Guangdong · Age: 1890 yrs

Specialists

Showing 25 of 72View all specialists →
NM
Nisha Acharya, MD MS
Specialist
PI on 4 active trials2 Uveitis publications
TM
Tiarnan DL Keenan, M.D.
BETHESDA, MD
Specialist
PI on 2 active trials
JS
Justine R Smith
Specialist
3 Uveitis publications
SC
Soon-Phaik Chee
Specialist
2 Uveitis publications
IT
Ilknur Tugal-Tutkun
Specialist
2 Uveitis publications
AR
Athimalaipet V Ramanan
Specialist
3 Uveitis publications
MM
Manabu Mochizuki
Specialist
2 Uveitis publications
ZT
Zheng Xian Thng
Specialist
2 Uveitis publications
PM
Panayiotis Maghsoudlou
Specialist
2 Uveitis publications
MZ
Manfred Zierhut
Specialist
2 Uveitis publications
AG
Amod Gupta
Specialist
2 Uveitis publications
SE
Simon J Epps
Specialist
1 Uveitis publication
PM
Parthopratim Dutta Majumder
Specialist
2 Uveitis publications
CG
Catherine M Guly
Specialist
3 Uveitis publications
DS
Derrick P Smit
Specialist
3 Uveitis publications
EC
Emmett T Cunningham
SAN FRANCISCO, CA
Specialist
3 Uveitis publications
AD
Andrew D Dick
Specialist
3 Uveitis publications
JM
Joyce H Yamamoto, MD
Specialist
PI on 2 active trials
NM
Nisha Acharya, MD, MS
Specialist
PI on 4 active trials2 Uveitis publications
AM
Arnd Heiligenhaus, MD
Specialist
PI on 3 active trials1 Uveitis publication
EM
Eric B Suhler, MD
PORTLAND, OR
Specialist
PI on 2 active trials
EM
Emily Y Chew, M.D.
BETHESDA, MD
Specialist
PI on 8 active trials
JM
James T Rosenbaum, MD
SARASOTA, FL
Specialist
PI on 2 active trials
AM
Ahmad M Mansour, MD
Specialist
PI on 3 active trials

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Financial Resources

1 resources

DUREZOL

Novartis

Blebitis

Unverified — confirm before calling
copay card
Copay CardPatient Assistance
Accepting applications

Travel Grants

No travel grants are currently matched to Uveitis.

Search all travel grants →NORD Financial Assistance ↗

Community

Open UveitisForum →

No community posts yet. Be the first to share your experience with Uveitis.

Start the conversation →

Latest news about Uveitis

Disease timeline:

New recruiting trial: Safety, Tolerability, and Distribution of Laquinimod Eye Drops : The LION Study

A new clinical trial is recruiting patients for Uveitis

New recruiting trial: Minocycline for Chronic Autoimmune Uveitis

A new clinical trial is recruiting patients for Uveitis

New recruiting trial: The Cohort Study of Uveitis Patients

A new clinical trial is recruiting patients for Uveitis

New recruiting trial: Intravitreal Adalimumab Versus Subcutaneous Adalimumab in Non-infectious Uveitis

A new clinical trial is recruiting patients for Uveitis

New recruiting trial: Suprachoroidal Triamcinolone in Macular Edema for Patients With Non-Infectious Uveitis Resistant to Subtenon Triamcinolon

A new clinical trial is recruiting patients for Uveitis

New recruiting trial: A Study of YUTIQ® 0.18 mg Intravitreal Implant for the Management of Chronic Non-infectious Uveitis

A new clinical trial is recruiting patients for Uveitis

New recruiting trial: RChildUV:Study on Non-infectious Chronic Uveitis in Pediatric Age

A new clinical trial is recruiting patients for Uveitis

New recruiting trial: Metagenomics for Ocular Inflammation

A new clinical trial is recruiting patients for Uveitis

New recruiting trial: Screening for Oculocerebral Lymphoma with the Phenotype of NK Cells in Patients with Uveitis

A new clinical trial is recruiting patients for Uveitis

New recruiting trial: Lyon Uveitis Study

A new clinical trial is recruiting patients for Uveitis

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Uveitis

Are there clinical trials for Uveitis?

Yes — 18 recruiting clinical trials are currently listed for Uveitis on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Uveitis?

25 specialists and care centers treating Uveitis are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.

What treatment and support options exist for Uveitis?

3 patient support programs are currently tracked on UniteRare for Uveitis. See the treatments and support programs sections for copay assistance, eligibility, and contact details.